| Document |
Document Title |
|
WO/2020/086890A1 |
The invention provides novel co-crystals of epicatechin with a carboxy-N-heterocyclic co-crystal former such as trigonelline or proline and their pharmaceutical compositions. Methods of preparing the co-crystals and methods of using them...
|
|
WO/2020/082435A1 |
A preparation method for a cisatracurium besilate injection without preservatives. Each 1000 ml of the injection contains the following components by weight: 2-10 g of cisatracurium besilate and a proper amount of benzenesulfonic acid. T...
|
|
WO/2020/086732A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2019/190175A9 |
The present invention relates to a method for differentiating motor neurons from tonsil-derived mesenchymal stem cells, and a cell therapy agent using same. The differentiation method of the present invention exhibits high differentiatio...
|
|
WO/2020/079203A1 |
The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2
-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one useful as pharmaceutically active compounds.
|
|
WO/2020/080641A1 |
The present invention relates to a composition for preventing or treating AMPK-related diseases, comprising a Gynostemma longipes VK1 extract or a compound isolated therefrom as an active ingredient. It is found that the Gynostemma longi...
|
|
WO/2020/079299A1 |
Microspheres for the treatment of musculoskeletal and vascular skin or dermatological disorders. The present invention relates to microspheres which are formed by a core comprising a triblock copolymer non-ionic surfactant, a halogenated...
|
|
WO/2020/078445A1 |
A pharmaceutical combination or a pharmaceutical composition for the treatment of fibrotic diseases, and a use for said pharmaceutical combination or pharmaceutical composition in the preparation of drugs for preventing and/or treating f...
|
|
WO/2020/077412A1 |
The present disclosure relates to methods of administering a gene therapy construct comprising RNA interference (RNAi) reagents, such as short hairpin microRNA (shmiR), in combination with PABPN1 replacement reagents, such as polynucleot...
|
|
WO/2020/075845A1 |
[Problem] To provide a potential candidate for preventing or treating diseases or disorders that are related to glucose metabolism by discovering a substance that can induce the expression of a GLUT family. [Solution] Through several asp...
|
|
WO/2020/074952A1 |
Provided are a pharmaceutical composition comprising zinc, leucine, and omega-3 fatty acids, formulated for oral delivery; a kit comprising the pharmaceutical composition; and methods of promoting recovery of pelvic floor muscles in a po...
|
|
WO/2020/070236A1 |
The invention provides a VMAT2 blocking compound for use in a method of treating a subject suffering from a movement disorder; which method comprises administering to the subject a therapeutically effective amount of the VMAT2 blocking c...
|
|
WO/2020/070506A1 |
The present invention provides a compound for use in preventing or treating overtraining in a subject, wherein the compound is selected from (i) (R)-3-hydroxybutyrate; (ii) an ester of (R)-3-hydroxybutyrate; and (iii) an oligomer obtaina...
|
|
WO/2020/072997A1 |
Methods and compositions for relieving general and chronic fatigue, restoring energy, rejuvenating sore muscles, and relieving associated pain by administering a composition including caffeine, and a cannabis component having one or more...
|
|
WO/2020/072574A1 |
Processes for production of a composition containing active follistatin via spray/heat drying of a biological source containing follistatin as well as compositions containing this active follistatin and methods for use in increasing musc...
|
|
WO/2020/063976A1 |
Provided are a fused heterocyclic biaryl benzyl alcohol compound, a preparation method, and use. The fused heterocyclic biaryl benzyl alcohol compound is as represented by formula (IA), has good inhibition activity for a BRD enzyme, and ...
|
|
WO/2020/063178A1 |
A gene editing composition or kit used for in vivo gene therapy, comprising: 1) sgRNA that is linked to a nucleic acid molecule of a binding protein and that targets a target mutant gene, or a coding sequence thereof, 2) a template nucle...
|
|
WO/2020/067435A1 |
The purpose of the present invention is to provide: a method for producing a high-quality graft from differentiation-induced cells derived from a pluripotent stem cell; a graft produced by using the method; and a method for treating a di...
|
|
WO/2020/058072A1 |
The present invention relates to novel SRC inhibitor compounds for improving skeletal muscle regeneration to maintain or increase muscle function and/or muscle mass by modulating muscle stem cells. For example, the present invention is u...
|
|
WO/2020/058071A1 |
The present invention relates to novel Raf-1 kinase inhibitor compounds for improving skeletal muscle regeneration to maintain or increase muscle function and/or muscle mass by modulating muscle stem cells. For example, the present inven...
|
|
WO/2020/060264A1 |
The present invention relates to a composition comprising a sulforaphane derivative for preventing, treating, or alleviating muscle atrophy and sarcopenia. The composition is not toxic to C2C12 cells and can effectively suppress muscle a...
|
|
WO/2020/058482A1 |
The present invention refers to the use of boron or a boron compound for the treatment of muscular dystrophies. The experimental data obtained in vitro and in vivo by the inventors demonstrate that these compounds improve certain phenoty...
|
|
WO/2020/056459A1 |
The present disclosure provides a method of treating a wasting disorder in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signalling. The present disclosure also provides a method of treatin...
|
|
WO/2020/060384A1 |
Powders impregnated with concentrated dehydrated Curcuma longa (turmeric) rhizome extracts and containing a concentrated dehydrated Hibiscus sabdariffa (Jamaica) flower extract, and the method for preparing same. A food product comprisin...
|
|
WO/2020/055240A1 |
Novel methods for treating condition, disorder and/or symptom which is alleviated by the inhibition of neuromuscular transmission in a subject are provided herein. The invention also provides binding agents for use in treating the same.
|
|
WO/2020/054821A1 |
The present invention addresses the problem of developing, by focusing on the central role of group 2 innate lymphoid cells (ILC2) in the immune system, a drug that is capable of inhibiting the activity of ILC2. The present invention has...
|
|
WO/2020/056204A1 |
Methods and kits for treating or alleviating masseter muscle hypertrophy by local administration of a Clostridial derivative, such as a botulinum toxin, to the masseter muscle are described. Methods and kits for reducing lower face width...
|
|
WO/2020/055241A1 |
Novel methods for treating a condition or disorder associated with impaired neuromuscular transmission,such as MuSK myasthenia gravis(MuSK MG), in a subject are provided herein. Novel methods for treating a symptom associated with impair...
|
|
WO/2020/055186A1 |
The present invention relates to a composition for preventing or treating obesity or sarcopenia, containing ATPase inhibitory factor 1 (IF1) and, more specifically, to a pharmaceutical composition and a food for preventing or treating ob...
|
|
WO/2020/056269A1 |
Disclosed herein are methods for treating centronuclear myopathies, such as myotubular myopathy, in a subject in need thereof, comprising administering to the subject in need thereof an effective amount of 3-{[(3S)-4-(6,6-dimethyl-4-oxo-...
|
|
WO/2020/049670A1 |
Provided as a technique for preparing an aqueous formulation of dantrolene or a pharmacologically acceptable salt thereof quickly and easily is a dantrolene aqueous formulation containing dantrolene or a pharmacologically acceptable salt...
|
|
WO/2020/051344A1 |
This invention is directed to selective androgen receptor degrader (SARD) compounds including heterocyclic rings and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant...
|
|
WO/2020/050403A1 |
This method for preventing muscle melting that occurs in the muscles of Salmoniformes is characterized in that a microsporidian expellant containing a benzimidazole-based compound as an active component is administered. The microsporidia...
|
|
WO/2020/051282A1 |
The present disclosure relates to Branaplam solid state forms, Branaplam salts and solid states thereof, processes for preparation thereof, pharmaceutical compositions and methods of use thereof. -
|
|
WO/2020/046466A1 |
Methods for alleviating one or more symptoms and/or inhibiting muscle disuse atrophy in mammals via administration of compositions of egg powder protein are provided.
|
|
WO/2020/044133A1 |
Disclosed herein are methods and compositions comprising adherent stromal cells.
|
|
WO/2020/045607A1 |
Provided is a stable pharmaceutical composition for oral administration that exhibits rapid drug elution in a pharmaceutical composition for oral administration containing 6-(4,4-dimethylcyclohexyl)-4-[(1,1-dioxo-1λ6-thiomorpholin-
4-yl...
|
|
WO/2020/040522A1 |
The present invention relates to a pharmaceutical composition for preventing or treating muscle diseases, comprising an extract of Codonopsis lanceolata as an effective component. More specifically, the extract of Codonopsis lanceolata o...
|
|
WO/2020/040615A1 |
The present invention relates to a composition for preventing or treating muscular diseases, or for improving muscular functions, containing gagnlioside. More specifically, the present invention relates to a pharmaceutical composition fo...
|
|
WO/2020/041750A1 |
The present invention provides a method of treating a disorder associated with muscle weakness in a subject, comprising administering to the subject a controlled-release composition comprising an effective amount of ribitol and/or ribose...
|
|
WO/2020/040432A1 |
The present invention relates to a pharmaceutical composition for preventing or treating muscle diseases, the composition containing a ginseng berry (Panax ginseng berry) extract as an active ingredient. The composition, according to the...
|
|
WO/2020/037895A1 |
An application of geniposide in promoting the formation of skeletal muscle fast muscle. The sources of geniposide comprise: gardenia meal, gardenia fruit, eucommia ulmoides, rehmannia glutinosa, achyranthes bidentata, hedyotis diffusa, a...
|
|
WO/2020/039088A2 |
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
|
|
WO/2020/036934A1 |
Provided herein are methods for treating, delaying progression of, or reducing the severity of amyotrophic lateral sclerosis (ALS) in a subject through administration of therapeutically effective amounts of agents (e.g., JAK kinase inhib...
|
|
WO/2020/037161A1 |
Aspects of the application relate to compositions and methods for treating spinal muscular atrophy in a subject. In particular, this application provides therapeutic combinations of a recombinant nucleic acid that encodes the survival of...
|
|
WO/2020/032038A1 |
The present invention provides a compound represented by formula (I), which has high specificity and high selectivity for monoamine oxidase B, and which is capable of imaging monoamine oxidase B with a good sensitivity, or a pharmaceutic...
|
|
WO/2020/033473A1 |
Provided herein are chimeric transactivator minigenes, where the alternative splicing of the minigene determines whether a transactivator is expressed. Expression of the transactivator results in the transcription of a target gene that i...
|
|
WO/2020/027239A1 |
The present invention provides an epitope peptide derived from CDCA1 that has the ability to induce cytotoxic T cells. The present invention also provides a polynucleotide encoding the peptide, an antigen-presenting cell presenting the p...
|
|
WO/2020/024002A1 |
The invention relates to a composition comprising a first PEGylated tetanus neurotoxin (PEG-TeNT) comprising tetanus neurotoxin (TeNT) conjugated to polyethylene glycol (PEG) and a second TeNT. The invention also relates to various PEG-T...
|
|
WO/2020/027586A1 |
The present invention relates to a composition for accelerating muscle differentiation, comprising gallic acid as an active ingredient, wherein the active ingredient of the present invention, gallic acid, has the effects of increasing ce...
|
